Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
HIF-1 and tumor progression: pathophysiology and therapeutics — Gregg L. Friedman (2002) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
HIF-1 and tumor progression: pathophysiology and therapeutics
Shared by
Gregg L. Friedman
Johns Hopkins University
HIF-1 and tumor progression: pathophysiology and therapeutics
Article
2002
en
Related publications
Article
2000
Hypoxia, Clonal Selection, and the Role of HIF-1 in Tumor Progression
Gregg L. Friedman
Article
1997
V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression.
Bing‐Hua Jiang
,
Faton Agani
,
Antonino Passaniti
,
Gregg L. Friedman
Authors
Gregg L. Friedman
Johns Hopkins University
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Article
2000
Series Introduction: Tissue ischemia: pathophysiology and therapeutics
Gregg L. Friedman
Article
2009
RETRACTED: Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization
KangAe Lee
,
Huafeng Zhang
,
David Z. Qian
,
Sergio Rey
,
Jun O. Liu
,
Gregg L. Friedman
Article
2021
Interleukin-1 in tumor progression, therapy, and prevention
Cecília Garlanda
,
Alberto Mantovani
Discussion(0)
No comments yet. Be the first to comment.